A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
NCT ID: NCT05538130
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
124 participants
INTERVENTIONAL
2022-11-30
2028-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day.
* In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933).
Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monotherapy Dose Escalation (Phase 1a)
Participants will receive PF-07799544
PF-07799544
Tablet
encorafenib
Capsule
Phase 1b Substudy B Combination Dose Escalation
Participants will receive PF-07799544 and PF-07799933
PF-07799544
Tablet
PF-07799933
Tablet
Phase 1b Substudy B Combination Dose Expansion
Participants will receive PF-07799544 and PF-07799933
PF-07799544
Tablet
PF-07799933
Tablet
Phase 1b Substudy C Combination Dose Expansion
Participants will receive PF-07799544 and PF-07799933
PF-07799544
Tablet
PF-07799933
Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-07799544
Tablet
PF-07799933
Tablet
encorafenib
Capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation
* For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma
* For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma,
* For Substudy B and C, measurable disease by RECIST version 1.1
* For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II/III alteration in tumor tissue and/or blood
* For Substudy C, evidence of a BRAF founder alteration (non-V600 Class II/III BRAF alteration)
Exclusion Criteria
* History or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama, United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Alabama at Birmingham - Phase I Clinical Trials Unit
Birmingham, Alabama, United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
Highlands Oncology Group
Rogers, Arkansas, United States
Highlands Oncology Group, PA
Springdale, Arkansas, United States
The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate
Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
UCSF Medical Center, Investigational Pharmacy
San Francisco, California, United States
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only)
Santa Monica, California, United States
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center
Tampa, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Moffitt McKinley Hospital
Tampa, Florida, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Brigitte Harris Cancer Pavilion
Detroit, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
HealthPartners Frauenshuh Cancer Center
Saint Louis Park, Minnesota, United States
Methodist Hospital Inpatient Pharmacy
Saint Louis Park, Minnesota, United States
HealthPartners Cancer Center at regions Hospital
Saint Paul, Minnesota, United States
Regions Hospital Pharmacy
Saint Paul, Minnesota, United States
MSK Basking Ridge.
Basking Ridge, New Jersey, United States
MSK Monmouth.
Middletown, New Jersey, United States
MSK Bergen.
Montvale, New Jersey, United States
Optum Medical Care, PC
Brewster, New York, United States
MSK Commack.
Commack, New York, United States
MSK Westchester.
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center 53rd street.
New York, New York, United States
Columbia University Irving Medical Center
New York, New York, United States
Columbia University Medical Center - Neurological Institute of New York
New York, New York, United States
CUIMC Research Pharmacy
New York, New York, United States
The Trustees of Columbia University
New York, New York, United States
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, United States
Brooklyn Radiation Oncology, PC
Richmond Hill, New York, United States
MSK Nassau.
Uniondale, New York, United States
Clinical Research Alliance
Westbury, New York, United States
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States
Providence Portland Medical Center
Portland, Oregon, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute- Pharmacy
Nashville, Tennessee, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
University of Washington Medical Center
Seattle, Washington, United States
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Centro de Oncologia - CEON+ - Unidade São Caetano do Sul
São Caetano do Sul, São Paulo, Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada
Rabin Medical Center
Petah Tikva, Central District, Israel
Sheba Medical Center
Ramat Gan, Central District, Israel
Hadassah Medical Center
Jerusalem, Jerusalem, Israel
Soroka Medical Center
Beersheba, Southern District, Israel
Sourasky Medical Center
Tel Aviv, TELL ABĪB, Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C4901001
Identifier Type: -
Identifier Source: org_study_id